Neurocrine Biosciences | NBIX - Sales Revenues


Neurocrine Biosciences reported $794.9M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
Dynavax Technologies USD 94.9M 540K Sep/2025
Exelixis USD 597.8M 29.5M Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Halozyme Therapeutics USD 354M 148M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 2.42M 2M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Repligen USD 189M 7M Sep/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025